Halozyme Therapeutics Past Earnings Performance
Past criteria checks 5/6
Halozyme Therapeutics has been growing earnings at an average annual rate of 33.9%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 32.4% per year. Halozyme Therapeutics's return on equity is 86.7%, and it has net margins of 41.4%.
Key information
33.9%
Earnings growth rate
35.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 32.4% |
| Return on equity | 86.7% |
| Net Margin | 41.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal
Nov 20Halozyme: Looking For More Growth Following Record Q3 Earnings
Nov 05Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet
Oct 29
Halozyme Therapeutics: Behind The Pullback
Oct 22Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals
Aug 14Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Aug 13Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar
Jul 17Halozyme Therapeutics: The Story Brightens
Jun 07Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Apr 26Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
Apr 10Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?
Apr 05Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares
Mar 15Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 23Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
Jan 26These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely
Jan 10Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price
Dec 14Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Sep 22Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jul 04We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt
May 09Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?
Mar 28Revenue & Expenses Breakdown
How Halozyme Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 947 | 392 | 150 | 0 |
| 30 Jun 24 | 873 | 337 | 144 | 0 |
| 31 Mar 24 | 863 | 319 | 147 | 0 |
| 31 Dec 23 | 829 | 282 | 149 | 0 |
| 30 Sep 23 | 781 | 254 | 127 | 0 |
| 30 Jun 23 | 774 | 234 | 127 | 0 |
| 31 Mar 23 | 705 | 182 | 145 | 0 |
| 31 Dec 22 | 660 | 202 | 122 | 0 |
| 30 Sep 22 | 581 | 211 | 120 | 0 |
| 30 Jun 22 | 487 | 366 | 98 | 0 |
| 31 Mar 22 | 472 | 435 | 53 | 0 |
| 31 Dec 21 | 443 | 403 | 50 | 0 |
| 30 Sep 21 | 463 | 409 | 47 | 0 |
| 30 Jun 21 | 412 | 229 | 46 | 0 |
| 31 Mar 21 | 331 | 163 | 44 | 0 |
| 31 Dec 20 | 268 | 129 | 46 | 0 |
| 30 Sep 20 | 200 | 22 | 48 | 0 |
| 30 Jun 20 | 180 | -40 | 54 | 0 |
| 31 Mar 20 | 164 | -80 | 61 | 0 |
| 31 Dec 19 | 196 | -72 | 77 | 0 |
| 30 Sep 19 | 203 | -40 | 71 | 0 |
| 30 Jun 19 | 182 | -43 | 68 | 0 |
| 31 Mar 19 | 178 | -51 | 65 | 0 |
| 31 Dec 18 | 152 | -80 | 61 | 0 |
| 30 Sep 18 | 281 | 46 | 58 | 0 |
| 30 Jun 18 | 319 | 76 | 56 | 0 |
| 31 Mar 18 | 318 | 68 | 55 | 0 |
| 31 Dec 17 | 317 | 63 | 54 | 0 |
| 30 Sep 17 | 166 | -88 | 51 | 0 |
| 30 Jun 17 | 134 | -120 | 50 | 0 |
| 31 Mar 17 | 134 | -116 | 48 | 0 |
| 31 Dec 16 | 147 | -103 | 46 | 0 |
| 30 Sep 16 | 160 | -71 | 44 | 0 |
| 30 Jun 16 | 149 | -67 | 43 | 0 |
| 31 Mar 16 | 159 | -37 | 41 | 0 |
| 31 Dec 15 | 135 | -32 | 40 | 0 |
| 30 Sep 15 | 113 | -42 | 38 | 0 |
| 30 Jun 15 | 107 | -38 | 36 | 0 |
| 31 Mar 15 | 82 | -57 | 35 | 0 |
| 31 Dec 14 | 75 | -68 | 36 | 0 |
| 30 Sep 14 | 57 | -85 | 37 | 0 |
| 30 Jun 14 | 59 | -84 | 36 | 0 |
| 31 Mar 14 | 55 | -91 | 35 | 0 |
| 31 Dec 13 | 55 | -83 | 32 | 0 |
Quality Earnings: HALO has high quality earnings.
Growing Profit Margin: HALO's current net profit margins (41.4%) are higher than last year (32.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HALO has become profitable over the past 5 years, growing earnings by 33.9% per year.
Accelerating Growth: HALO's earnings growth over the past year (54.6%) exceeds its 5-year average (33.9% per year).
Earnings vs Industry: HALO earnings growth over the past year (54.6%) exceeded the Biotechs industry 16.6%.
Return on Equity
High ROE: Whilst HALO's Return on Equity (86.69%) is outstanding, this metric is skewed due to their high level of debt.